Quidelortho Corp Intrinsic Stock Value – Quidelortho Corp. Beats Expectations in Q4 with Non-GAAP EPS of $1.76 and Revenue of $866.5M
February 21, 2023
Trending News 🌥️
Quidelortho Corp ($NASDAQ:QDEL)., a leading provider of diagnostic and molecular testing solutions, has reported outstanding fourth quarter financial results that surpassed expectations. Quidel reported a Non-GAAP EPS (earnings per share) of $1.76, which is higher by $0.34 than the estimated figure.
Additionally, the reported revenue of $866.5M exceeded the forecasted amount by a significant margin of $90.69M. This impressive financial performance is a testament to the hard work and dedication of the company’s employees and partners. Their commitment to providing superior quality testing solutions and delivering excellent results has allowed Quidel to continue to remain competitive within the industry while meeting the financial goals set by its investors. Given the current challenging economic environment, the success of Quidelortho Corp. in achieving these financial objectives is even more remarkable. The organization has effectively managed to maintain healthy profit margins and sustain its consistent growth trajectory despite the adverse conditions in the markets. The strong financial performance of Quidelortho Corp. in the fourth quarter has certainly exceeded all expectations. Investors are likely to retain their enthusiasm for the company’s stock in the upcoming quarters and Quidelortho Corp. is poised to capitalize on this positive sentiment in order to further grow its presence in the industry.
Market Price
Their non-GAAP EPS was reported to be $1.76 and their revenue to be $866.5M. On Wednesday, the company opened at $85.2, then increased by 0.5%, closing at $86.2. This is up fromlast closing price of 85.8, indicating that investors had a generally favorable reaction to the results. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Quidelortho Corp. More…
| Total Revenues | Net Income | Net Margin |
| 3.27k | 548.7 | 20.5% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Quidelortho Corp. More…
| Operations | Investing | Financing |
| 885.3 | -1.64k | 252 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Quidelortho Corp. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 8.86k | 3.92k | 72.61 |
Key Ratios Snapshot
Some of the financial key ratios for Quidelortho Corp are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 82.8% | 110.9% | 24.9% |
| FCF Margin | ROE | ROA |
| 27.1% | 10.6% | 5.7% |
Analysis – Quidelortho Corp Intrinsic Stock Value
At GoodWhale, we have conducted an analysis of QUIDELORTHO CORP‘s wellbeing. Therefore, investing in QUIDELORTHO CORP at this price could present a good opportunity for those currently in the market for stocks. More…
Peers
Quidel Corporation is a leading provider of diagnostic healthcare solutions serving both the professional and consumer markets. The company manufactures and sells a broad range of diagnostic products, including immunoassays, molecular diagnostics, and infectious disease tests. Quidel’s products are used in hospitals, physician offices, clinics, and commercial laboratories, as well as at-home for self-testing. Quidel has a strong portfolio of products and a long history of providing high-quality diagnostics.
However, the company faces competition from a number of other companies, including LifePoint Inc, Bloom Health Partners Inc, and Talis Biomedical Corp.
– LifePoint Inc ($OTCPK:LFPI)
LifePoint Inc is a company that provides healthcare services. It has a market cap of 10.21k as of 2022 and a Return on Equity of 8.83%. The company has a strong ROE, which indicates that it is efficient in using its assets to generate profits. The company is doing well financially and is expected to continue to grow in the future.
– Bloom Health Partners Inc ($OTCPK:BLMHF)
The company’s market cap is 2.86M as of 2022. The company’s ROE is 26.8%. The company’s main products and services are health insurance, health care, and benefits administration. Health insurance coverage is provided to individuals, families, and businesses through a variety of plans. Health care services are delivered through a network of providers. Benefits administration services are provided to employers and employees.
– Talis Biomedical Corp ($NASDAQ:TLIS)
Talis Biomedical Corp is a medical technology company that develops and commercializes products based on its proprietary technology Platform for the early detection of infectious diseases. The Platform is designed to provide rapid, sensitive, and accurate detection of a wide range of infectious diseases. Talis Biomedical’s products are based on its proprietary platform technology, which is designed to provide rapid, sensitive, and accurate detection of a wide range of infectious diseases. Talis Biomedical’s products are intended for use in a variety of settings, including hospital emergency departments, primary care offices, and home health settings. Talis Biomedical’s products are currently in development and have not been cleared for commercial sale by the U.S. Food and Drug Administration.
Summary
Overall, Quidelortho’s reported results demonstrated strong organic growth, improved gross margins, and a healthy balance sheet, all of which remain favorable for investors looking to take a position in the company.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
